10 Firms Crushing the Market

7. Hims & Hers Health, Inc. (NYSE:HIMS)

Telehealth company Hims & Hers extended its winning streak for a third straight day on Tuesday, jumping 15.92 percent to finish at $64 apiece after earning a stock rating upgrade from an investment firm.

On Tuesday, Truist Securities raised its price target for Hims & Hers Health, Inc. (NYSE:HIMS) to $45 from $33 previously while maintaining a “hold” rating on the stock.

This came after its first quarter earnings performance, which Truist referred to as a “mixed bag” after a revenue beat driven by strong sales in GLP-1, reaffirmed revenue guidance for the year, alongside a higher EBITDA forecast.

Truist’s rating also included Hims & Hers Health, Inc.’s (NYSE:HIMS) recent partnership with Novo Nordisk to jointly market the blockbuster Wegovy drugs on the former’s telehealth platform.

In its latest earnings release, Hims & Hers Health, Inc. (NYSE:HIMS) said that its net income expanded by 346 percent to $49.5 million from the $11.1 million registered in the same period last year, while revenues soared by 111 percent to $586 million from $278.2 million year-on-year.

The company said that its strong performance underpinned its updated 2025 guidance, with full-year revenues expected to settle between $2.3 billion and $2.4 billion, and the second quarter to end at $530 million to $550 million.